FDA accepts Enzychem’s IND for trial of Covid-19 treatment candidate

The FDA has accepted Enzychem’s IND for EC-18 trial to prevent ARDS due to Covid-19 pneumonia. (Credit: Thor Deichmann from Pixabay)